NewAmsterdam Pharma Co N.V. 8-K

What Happened NewAmsterdam Pharma Co. N.V. filed a Form 8-K on January 9, 2026 (Item 2.02 and Reg FD disclosure) to highlight its 2025 achievements and outline 2026 strategic priorities. The filing announced that, as of December 31, 2025, the company’s unaudited cash, cash equivalents and marketable securities totaled approximately $729 million. The company furnished a press release dated January 9, 2026 as Exhibit 99.1 to the 8-K; the report was signed by CFO Ian Somaiya.

Key Details

• Filing date: January 9, 2026 (Form 8-K; Item 2.02 and Regulation FD disclosure).
• Liquidity position: approximately $729 million in unaudited cash, cash equivalents and marketable securities as of December 31, 2025.
• Disclosure format: information announced via press release (Exhibit 99.1) and furnished under Reg FD.
• Authorized signatory: Ian Somaiya, Chief Financial Officer, signed the 8-K.

Why It Matters A reported cash and marketable securities balance of $729 million is a concrete, near-term liquidity metric investors use to assess the company’s ability to fund operations, development programs and strategic priorities without immediate reliance on external financing. While the 8-K did not provide revenue or earnings figures, the cash position is material for understanding financial flexibility through 2026. Investors should review the full press release (Exhibit 99.1) and subsequent filings for more detail on operating results, revenue or any planned use of cash.